X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs STRIDES PHARMA SCIENCE - Comparison Results

AUROBINDO PHARMA     Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA STRIDES PHARMA SCIENCE AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 13.7 19.6 69.7% View Chart
P/BV x 2.8 0.8 327.4% View Chart
Dividend Yield % 0.5 0.6 78.7%  

Financials

 AUROBINDO PHARMA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
AUROBINDO PHARMA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8091,147 70.5%   
Low Rs504642 78.5%   
Sales per share (Unadj.) Rs281.1317.2 88.6%  
Earnings per share (Unadj.) Rs41.47.8 527.2%  
Cash flow per share (Unadj.) Rs50.925.1 203.1%  
Dividends per share (Unadj.) Rs2.502.00 125.0%  
Dividend yield (eoy) %0.40.2 170.3%  
Book value per share (Unadj.) Rs199.4274.3 72.7%  
Shares outstanding (eoy) m585.8889.50 654.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.32.8 82.8%   
Avg P/E ratio x15.9114.0 13.9%  
P/CF ratio (eoy) x12.935.7 36.1%  
Price / Book Value ratio x3.33.3 101.0%  
Dividend payout %6.025.5 23.7%   
Avg Mkt Cap Rs m384,63080,058 480.4%   
No. of employees `00017.32.5 691.3%   
Total wages/salary Rs m21,3084,341 490.9%   
Avg. sales/employee Rs Th9,500.711,325.8 83.9%   
Avg. wages/employee Rs Th1,229.41,731.4 71.0%   
Avg. net profit/employee Rs Th1,397.9280.1 499.2%   
INCOME DATA
Net Sales Rs m164,66628,394 579.9%  
Other income Rs m1,020941 108.4%   
Total revenues Rs m165,68629,334 564.8%   
Gross profit Rs m37,7183,965 951.2%  
Depreciation Rs m5,5801,540 362.2%   
Interest Rs m7771,962 39.6%   
Profit before tax Rs m32,3801,403 2,307.6%   
Minority Interest Rs m310-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m8,18397 8,409.8%   
Profit after tax Rs m24,229702 3,450.9%  
Gross profit margin %22.914.0 164.0%  
Effective tax rate %25.36.9 364.4%   
Net profit margin %14.72.5 595.1%  
BALANCE SHEET DATA
Current assets Rs m121,87824,836 490.7%   
Current liabilities Rs m86,80618,993 457.0%   
Net working cap to sales %21.320.6 103.5%  
Current ratio x1.41.3 107.4%  
Inventory Days Days13071 183.0%  
Debtors Days Days68113 60.3%  
Net fixed assets Rs m81,03734,289 236.3%   
Share capital Rs m586895 65.5%   
"Free" reserves Rs m116,21823,651 491.4%   
Net worth Rs m116,80424,546 475.9%   
Long term debt Rs m4,51215,513 29.1%   
Total assets Rs m211,05265,437 322.5%  
Interest coverage x42.71.7 2,487.6%   
Debt to equity ratio x00.6 6.1%  
Sales to assets ratio x0.80.4 179.8%   
Return on assets %11.84.1 291.0%  
Return on equity %20.72.9 725.2%  
Return on capital %27.46.9 396.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m80,72715,697 514.3%   
Fx outflow Rs m34,700735 4,718.6%   
Net fx Rs m46,02714,962 307.6%   
CASH FLOW
From Operations Rs m19,5481,871 1,045.0%  
From Investments Rs m-19,5705,826 -335.9%  
From Financial Activity Rs m8,642-10,157 -85.1%  
Net Cashflow Rs m8,922-2,615 -341.2%  

Share Holding

Indian Promoters % 54.1 27.7 195.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 37.8 21.0%  
FIIs % 27.7 8.6 322.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.9 39.4%  
Shareholders   69,601 56,241 123.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SUVEN LIFESCIENCES  ORCHID PHARMA LTD  SANOFI INDIA  TTK HEALTHCARE  SHASUN PHARMA  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 10.9% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 10.9% YoY). Sales on the other hand came in at Rs 53 bn (up 30.7% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS